Currently predicting for Thu, 4 Jun 2026

GERN Prediction Chart

GERN Predictions History

Latest community submissions for GERN.
Predictor Target Session Target Price Result Direction Accuracy Score
JS JS Pro
Oct 7, 2024 $4.34 +0.46% $4.15 X 95.42% 0
Oct 7, 2024 $4.40 +1.96% $4.15 X 93.87% 0
Oct 7, 2024 $4.37 +1.22% $4.15 X 94.63% 0
Oct 7, 2024 $4.50 +4.17% $4.15 X 91.57% 0
JS JS Pro
Jun 14, 2024 $4.70 -3.69% $4.87 V 96.51% 1
Jun 14, 2024 $4.76 -2.54% $4.87 V 97.66% 1
Jun 14, 2024 $4.80 -1.59% $4.87 V 98.61% 2
Jun 10, 2024 $4.47 -2.51% $5.04 X 88.78% 0
Jun 10, 2024 $4.52 -1.57% $5.04 X 89.64% 0
Jun 10, 2024 Bullish $5.04 V 1
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for GERN with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT GERON CORPORATION
Geron
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes a...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE